How we can utilize the Xpert MTB/RIF assay to decide on airborne infection isolation of inpatients with tuberculosis suspicion in Brazil: a brief review of the current data  by Resende, Mariângela Ribeiro
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5ear Editor,
owadays, for prevention of tuberculosis (TB) transmission
t health care facilities, the patient with a presumptive
iagnosis of infectious active TB requires airborne infec-
ion isolation (AII) until three negative respiratory specimens
–24 h apart (acid-fast bacilli strategy). However, with the
urrent use of rapid molecular assay, Xpert MTB/RIF assay®
Xpert, Cepheid, Sunnyvale, California), an update of this rec-
mmendation is necessary. Few studies have addressed this
peciﬁc issue, the majority of them performed in the United
tates. In a study using a decision analysis model, associ-
ted with primary data on costs and outcomes, the Xpert
TB/RIF assay to guide triage of inpatients with presumed
ulmonary TB observed a cost reduction of AII by $2278
er inpatient admission.1 Another observational cohort study
ith 207 inpatients demonstrated that all strategies based on
pert resulted on reduction of AII duration when compared
ith AFB management.2 In a prospective observational study,
ncluding 142 admissions, the comparison between serial spu-
um microscopy and a single Xpert MTB/RIF for triage of
atients for AII, resulted in identical sensitivity and nega-
ive predictive value, 89% and 99%, respectively.3 The clinical
rial “ACTG A5295/TBTC 34” showed that one or two Xperts
TB/RIF assay were each signiﬁcantly more  sensitive and spe-
iﬁc than three AFB smears for identifying culture positive
atients.4 In February 2015, based on an independent analysis
f “ACTG A5295/TBTC 34”, the US Food Drug and Admin-
stration approved the expansion the Xpert MTB/RIF assay
or AII deﬁnition in the United States based on the negative
redictive value of one or two specimen Xpert strategy for
bsence of MTB-complex on AFB smears were 99.7% and 100%,
espectively.5 To date we  are not aware of speciﬁc published
ecommendation of Xpert-strategy for AII deﬁnition in Brazil.
he data herein brieﬂy reviewed is indicative of the approachof using one or two Xpert MTB/RIF to replace the AFB strategy
for discontinuation of airborne infection isolation of patients
with presumed pulmonary TB at Brazilian health care facili-
ties.
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